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Influenza is a persistent threat to individual and global health. Seasonal influenza 
kills nearly 500,000 people globally each year. Influenza viruses have circulated within 
the human population, causing a significant disease burden. In order to create the most 
effective antiviral therapies, knowledge concerning all lineages of influenza must be 
studied accurately and thoroughly. The influenza virus itself is not always responsible for 
these mortalities, rather, the secondary bacterial infections associated with death. In order 
to protect the population and examine the secondary infections that arise, the kinetics of 
influenza must be studied entirely. To understand the kinetics, researchers are turning to 
the use of laboratory experimentation using ferrets as an effective model. This is done 
through the use of common laboratory procedures such as TCID50’s and 
hemagglutination assays. Through the use of these procedures, the kinetics of influenza A 
and B can be confirmed. Within this study, it was confirmed that influenza A infects both 
the upper and lower respiratory system, while influenza B infects the upper respiratory 
tract but fails to reach the lower lungs. Understanding the kinetics of influenza is the first 
step toward creating effective therapies to reduce the mortality and illness associated with 
the influenza virus infection. 
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Importance of Understanding Influenza 
Influenza is a highly contracted and contagious viral disease, infecting 5-20% of 
the world population each year (WebMD, 2020). According to the World Health 
Organization, tens of millions of people are infected with influenza during the flu season. 
Serious complications are rare for people infected with influenza, however, in the United 
States, there are more than ten thousand deaths due to influenza infection each year 
(Center for Disease Control and Prevention, 2020). According to the Center for Disease 
Control and Prevention (CDC), during the 2019-2020 flu season, starting October 1, 
2019, there were an estimated 32 million cases of influenza-like illnesses globallly. In the 
most recent flu season (2019-2020), there were 310,000 hospitalizations and 18,000 
deaths linked to influenza, and the season has not concluded as of the writing date 
(Center for Disease Control and Prevention, 2020).  
In most cases, influenza infections are not fatal. However, in some cases, 
treatment is needed to prevent further complications. If influenza is allowed to progress, 
moderate and severe secondary infections may arise. These progressive infections can 
develop into bronchitis, pneumonia, or sinus infections (Miko et al., 2019). Sinus and ear 
infections are examples of moderate complications that can arise from influenza. Serious 
complications that are triggered by an influenza infection include myocarditis, 
encephalitis, myositis, and multi-organ failure (Center for Disease Control and 
Prevention, 2019). Not only can influenza infection trigger secondary infections, it may 
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make chronic medical conditions worse (Center for Disease Control and Prevention, 
2019). Since influenza is a respiratory infection, patients with underlying respiratory 
complications possess a substantial risk when contracting influenza.  
There are many preventative procedures that should be considered for influenza, 
such as increased personal hygiene and receiving an annual flu vaccination. Flu vaccines 
have become increasingly popular and are easily accessible to the general public. The 
CDC estimates the flu vaccine as 40 to 60 percent effective among the overall population 
during seasons when circulating influenza viruses are well-matched with the strains 
included in the vaccine (Center for Disease Control and Prevention, 2020). In the most 
recent flu season (2019-2020), the CDC estimates that the vaccine has only been about 45 
percent effective. With the prevalence and known history of influenza, one might think 
that a more accurate and effective vaccination could be accessible, however, since it is 
difficult to predict which of the multiple strains or subtypes of influenza will be 
circulating in a given year, constant research is needed to prepare for the upcoming flu 
season.  
 
History of Influenza A and B in Humans 
Influenza first became recognized in 1889 as a bacterial infection, starting as an 
epidemic in Bukhara, Uzbekistan, that developed into a pandemic of Russian influenza 
within the same year (Erkoreka, 2009). An epidemic is defined as a disease that affects a 
large number of people within a community, while a pandemic is defined as an epidemic 
that has spread over multiple countries or continents (Intermountain Healthcare, 2020). 
The classification of influenza from an epidemic to a pandemic within the same year 
demonstrates the high transmissibility of the virus. During this time, railways and steam 
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trains were increasing in numbers, spreading the disease at alarming rates. A few years 
after the influenza pandemic had circulated the world, most clinicians accepted that 
“Pfeiffer’s bacillus”, a bacterium, was the leading cause of influenza. In 1918, influenza 
continued to spread around the world, infecting billions of people. During this wave, an 
estimate of 50 million to 100 million people died as a result of influenza infection 
(Hageman, 2020). Society was unable to keep this infectious disease under control with 
the therapies they were using to approach this pandemic. However, in 1933, the National 
Institute for Medical Research was able to identify influenza as a new class of pathogenic 
viruses (Brennan, 1987). This new classification of pathogens allows a way to distinguish 
different viral strains utilizing the haemagglutinin (H) and neuraminidase (N) antigens on 
the virus coat. In subsequent years, different strains such as the Asian flu (1957, H2N2), 
Hong Kong flu (1966, H3N2), and the 1976 swine flu (H1N1) demonstrated how new 
strains of influenza could emerge from livestock and wild animals.  
Of the four recognized influenza types, A, B, C, and D, influenza A causes the 
most morbidity in humans (Seladi-Schulman, 2019). Influenza A viruses (IAVs) are the 
only known influenza viruses to cause flu pandemics around the world (Center for 
Disease Control and Prevention, 2019). This strain of influenza can be found in many 
different species including but not limited to humans, birds, and swine (Center for 
Disease Control and Prevention, 2018). Due to the large diversity of hosts and influenza’s 
ability to change genetically, influenza A viruses are very diverse. Although influenza A 
is commonly thought to be one strain, many different subtypes arise to cause global 
epidemics. These viruses are divided into many subtypes based on the surface proteins H 
and N. There are 18 different H subtypes and 11 different N subtypes (Seladi-Schulman, 
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2010). There are currently 131 subtypes detected in nature, with A (H1N1 and H3N2) 
circulating in humans most predominantly (Center for Disease Control and Prevention, 
2019). The current H1N1 virus strain emerged in the spring of 2009 and has continued to 
undergo small genetic changes that yield changes to its antigenic properties, making this 
virus hard to target and allowing for elevated infectivity (Cheng & To, 2012). It is 
estimated that influenza A accounts for 75 percent of confirmed seasonal infections. 
(Seladi-Schulman, 2019).  
While influenza B viruses (IBVs) are unlike influenza A viruses in terms of 
genetics; symptoms associated with these two viruses are generally similar (Anthony, 
2018). IBVs are classified into two lineages: B/Yamagata and B/Victoria (Yang et al., 
2012). Given the fact that Influenza B viruses mutate at a much slower rate than IAVs in 
terms of genetics and antigenic properties, and that the primary host for IBV is human, 
there is a reduced chance of a possible pandemic concerning influenza B. Influenza B is 
commonly spread from human to human and is highly contagious similar to influenza A 
(Center for Disease Control and Prevention, 2019). While influenza A accounts for nearly 
75 percent of confirmed flu cases, influenza B accounts for the remaining 25 percent 
(Seladi-Schulman, 2019). Influenza B is still a strain that raises concern, however, as 
influenza B viruses have been perceived to circulate in particular time periods and 
geographical areas. The two strains of influenza B, Vic87 and Yam88, have been known 
to decline in infection magnitude and then re-emerge later in time, causing epidemics of 
influenza B viruses to fluctuate both periodically and geographically (Yang et al., 2012). 
Influenza B may not appear to be as high of a threat as IAV due to the slower evolution 
and antigenic drift, however, various mechanisms of insertion, deletion, and reassortment 
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within different lineages increase the genetic diversity of influenza B (Dudas et al., 
2014). Nonetheless, both influenzas raise concern to the public and the research behind 
the two types of influenza is constant and continuous.  
 
Ferrets as a Model System for Influenza Study 
 
For many years prior, mice have been used as a model system to study influenza 
viruses (Belser et al., 2011). The individual animals were low cost, readily available, and 
had extensive availability for the use of reagents and for transgenic lines with targeted 
gene disruptions. It was later found that most human influenza strains do not replicate 
efficiently in mice without prior virus adaptation, and the clinical signs commonly found 
in humans were not present in mice (Belser et al., 2011). Mice were deemed a poor 
model for the study of influenza, thus leading to the guinea pig model. Guinea pigs 
support the replication of influenza without prior adaptation, but like mice, do not 
replicate the clinical signs experienced by humans (Belser et al., 2011). Non-human 
primates were then used as a model, but proved to be exceedingly large and costly, and 
ethical considerations limited the use these species as a model (Belser et al., 2011). An 
improved model was needed, and the ferret was then introduced to the laboratory setting.  
The use of ferrets for the understanding of influenza viruses has broken ground in 
scientific research. Ferret models (Mustela putorius furo) have been established for many 
viruses that lead to respiratory infections (Matsuoka et al., 2009). Ferrets are a common 
mammalian model for certain studies as they are relatively small in size and they possess 
the ability to emulate numerous clinical features associated with human disease 
(Matsuoka et al., 2009). This is especially the case in regard to influenza. They provide 
an ideal model for an influenza study as they are naturally susceptible to human-adapted 
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influenza viruses, and when infected they display similar symptoms as humans 
(Matsuoka et al., 2009). These symptoms include fever, lethargy, nasal discharge, 
sneezing, and coughing. Not only do the two species exhibit similar clinical signs, the 
lung physiology of humans and ferrets is also relatively similar (Belser et al., 2019). The 
human and avian influenza viruses show similar patterns of binding to sialic acids on the 
cell surface, which are distributed throughout the respiratory tract in both humans and 
ferrets (Besler et al., 2019). Ferrets display a high susceptibility to influenza virus, and in 
1933, it was shown that an infected ferret is able to transmit the virus to healthy 
individuals within the ferret species (Smith et al., 1933). Human and avian viruses 
replicate efficiently in the respiratory tract of ferrets without prior adaptation, and 
enhanced pulmonary spread of virus is seen following infection with some highly 
pathogenic avian influenza (HPAI) viruses (Belser et al., 2011). Numerous symptoms 
found in humans during a seasonal influenza outbreak were also present in ferrets 
following experimental inoculation with these strains via the intranasal route (Moore et 
al., 2014). Elevated body temperatures can be detected as early as one day post-
inoculation and nasal discharge along with sneezing can be observed up to seven days 
post-inoculation (Zitzow et al. 2002). Upon collection of data, the blood and/or tissue 
samples can be collected from an inoculated ferret, and the presence of virus can be 
quantified. The use of ferrets in the study of influenza has proven to be highly successful 
and has offered crucial information for the understanding of influenza. 
Using ferrets as models to study the infectivity of influenza A and B in the upper 
and lower respiratory tract have proven useful to the understanding of these viruses. 
Studies were previously conducted using autopsy material from humans, so only changes 
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associated with lethal outcomes and late-stage disease had been characterized 
(Taubenberger & Morens, 2008). The infection of influenza goes far beyond this, varying 
with clinical progression and length of the disease before death. Concern about the 
emergence of an influenza pandemic caused by an HPAI virus (influenza A strain) makes 
reviewing the pathology of previous pandemics relevant. Both types of influenza display 
a standard pattern of infection in humans with an exponential increase in virus titer, 
which peaks around two to three days post infection, followed by an exponential decrease 
until days six to eight, with the virus titer ultimately undetectable in both the upper and 
lower respiratory systems (Baccam et al., 2006).  Aside from this, influenza A and B are 
known to differ in the rate of infectivity and the direction in which the virus travels, 
loosely defined as kinetics. The difference in kinetics between the two types is defined 
around the region of infection in the respiratory tract, specifically the upper and lower 
portions.  
Unlike influenza B, influenza A replicates in both the upper and lower respiratory 
tract (Baccam et al., 2006).  IAV can be detected in both the nasal passage and in the 
lower respiratory tract (lungs), for the duration of nine days post-inoculation (Kim et al., 
2015). The kinetics of influenza A are commonly studied, but information concerning the 
kinetics of influenza B is not nearly as abundant. Few studies with reliable data have been 
conducted concerning the lower and upper respiratory infections of influenza B. In a 
study by Kim (2015), the presence of virus was found in the nasal turbinate, but all 
samples collected showed no presence of influenza B in the trachea or lung. This is 
intriguing as influenza virus is thought to replicate in the epithelial cells throughout the 
respiratory tree (Taubenberger & Morens, 2008). People with chronic lung disease are 
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cautioned by the CDC to be cautious during the flu season as they are more at risk for the 
likelihood of severe disease and death. If influenza B is deemed to be absent in the lungs, 
those with chronic lung disease that have contracted an IBV can rest assured knowing 
that the likelihood of mortality is lowered. The absence of knowledge concerning the 
kinetics of influenza B suggests that more research is needed if the number of people 
infected by influenza is to decrease.  
 
Influenza and the General Public 
 
With the current coronavirus disease of 2019 (COVID-19) pandemic, it is evident 
why viral kinetics and the possible outcomes of viral infections should be studied. Every 
year, seasonal influenza makes a return with the possibility of catastrophic consequences 
when pandemics occur. While the importance of influenza pandemics has been well-
noted since 1918, the virus continues to infect thousands and kill an average of 500,000 
people globally each year (Fauci & Collins, 2012). The cases of influenza during a 
“normal” influenza season in the United States can reach extreme numbers of 20 to 50 
million cases of influenza and influenza-like illnesses (Clayville, 2011). The virus is 
continuously undergoing extensive genetic changes in addition to possessing the ability 
to transfer between species (Webster & Govorkova, 2015). This concept leads to high 
vulnerability in humans. If an event similar to the previously described occurs, a global 
health disaster can arise, such as the 1918 influenza pandemic. The 1918 pandemic killed 
an overwhelming fifty to one hundred million people worldwide (Institute of Medicine, 
2005). Not only did an extreme mortality rate affect the public, the world encountered 
enormous social and economic disruption. Influenza circulates widely and is constantly 
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evolving toward pandemic capability, as was seen in the pandemic of 1957, 1968, and 
2009. This indicates a clear danger of future pandemics caused by the influenza virus.  
One of the goals present in pandemic influenza research is to recognize and 
predict how viruses are evolving in wild animals toward a phenotype that is threatening 
to humans (Fauci & Collins, 2012). This research could allow society to stay one step 
ahead of the virus and be able to prepare for any future outbreaks. However, due to the 
constant evolution of the virus, continuous research is needed to keep up with the genetic 
changes undergone by influenza. If staying one step ahead fails and an outbreak occurs, 
information on how to decrease mortality of the virus in those already infected is crucial 
as well. Influenza in its entirety must be studied to prepare for a large outbreak, this 
includes thorough study of the kinetics of influenza infection.  Currently, little is known 
about the kinetics of influenza during infection due to its constant genetic evolution. 
Numerous studies are in place to try to comprehend the entirety of influenza and by the 
analysis and discovery of new information, influenza infection can be hindered or 
altogether stopped through the development of new antiviral therapies.  
 
Purpose 
Many studies have been conducted on the infectivity and kinetics of influenza A, 
however, influenza B has not been studied as thoroughly. It has been determined that 
influenza A has the ability to first infect the upper respiratory tract while later traveling to 
the lower respiratory system. Influenza B has been determined to infect the upper 
respiratory system, however less is known about its activity in the lungs. The kinetics of 
influenza A were tested and verified through this research and the kinetics of influenza B 
were investigated. The kinetics of influenza B were discovered and analyzed through the 
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use of ferrets and numerous laboratory procedures. Identifying and understanding the 
kinetics of influenza B infections will provide crucial information toward the 
understanding of the virus and could ultimately lead to development of more effective 








































Materials and Methods 
 
 
Timeline of Events 
 
Male ferrets from an influenza free ferret colony at Marshall Farms were brought 
to the University of South Dakota (USD), Sanford School of Medicine’s animal facility. 
Ferrets were acclimated for fourteen days, then tested to confirm that the antibody levels 
were in compliance with titer levels against the three viruses used in this study. All of the 
procedures and experiments were conducted within biosafety level 2 facilities and in 
accordance with parameters set individually by the Institutional Animal Care and Use 
Committee and the Institutional Biosafety Committee of USD. The experiment took place 
over a course of nineteen days post-inoculation. Days -4 to Day 0 were spent preparing, 
replicating, and plating cells for the remainder of the study. On day 0, different groups of 
ferrets (n=4) were inoculated with B/Phuket/3073/2013 (BYam), A/California/4/2009-
H1N, and B/Brisbane/60/2008 (BVic). On days one through ten, nasal washes were 
collected from the four ferrets and Madin-Darby Canine Kidney (MDCK) cells were 
inoculated with nasal washes to determine whether virus was present in the nasal area. To 
determine presence of virus, the MDCK cells were incubated for a period of 72 hours 
before the virus titer was read and quantified. To confirm the presence of virus, 
individual wells of the diluted nasal wash samples (n=4 per dilution) were tested for their 
ability to bind red blood cells, indicating presence of virus in the well.  Upon completion 
of all data collection, the results were then analyzed and compared.  
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MDCK Growth Medium 
MDCK growth medium was essential to support cellular growth in an artificial 
environment, providing nutrients necessary for cultured cells to survive and proliferate. 
Growth medium also provides the correct osmolality and pH for cells to thrive and 
replicate. Serum-containing, minimum essential medium (MEM) was used for this study. 
MEM includes higher concentrations of amino acids allowing for a closer approximation 
to the protein composition of mammalian cells. Growth medium was used for the growth 
of healthy cells as well as an additive to ensure MDCK cells reached a confluency of 
3x105 MDCK cells per 500 l of media. This allowed the cells used for infection with 
nasal wash to remain at similar quantities for each sample dilution analyzed. All cell 
culture techniques were performed under a sterile hood using aseptic techniques to ensure 
the solution was free of all microorganisms by sterilization.  A 500 mL sterile filter-top 
(Corning 430626) was attached to a one-liter sterile bottle, later connecting the two 
components to a pump system. To the filter-top, 100 mL 10X MEM (GIBCO 11430), 50 
mL of Fetal Bovine Serum (FBS)- Hyclone (previously heated-inactivated at 56C for 30 
minutes), 10 mL of Antibiotic/antimycotic solution and 10 mL MEM Vitamin solution 
was added to the filter-top. Fetal Bovine Serum was included because of its high quantity 
of hormones, carrier proteins, and macromolecular proteins allowing for growth 
enhancement of the MDCK cells. Antibiotic/antimycotic was added as a prophylactic to 
prevent contamination, and vitamins were added to the growth medium due to the 
inability of MDCK cells to synthesize vitamins independently. Ten mL L-glutamine was 
added to serve as an auxiliary energy source, providing nitrogen for the synthesis of 
proteins as the cells are rapidly dividing.  One mL Gentamicin (10 mg/cc) was added for 
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its anti-bacterial efficacy. The total volume of the sterile filter-top was brought to 500 mL 
with ddH2O (approximately 331 mL). Once filtration was complete, the pump was 
stopped and the resulting pressure was released. To the empty filter-top, 30 mL Sodium 
Bicarbonate (NaHCO3) was added to maintain the pH in the presence of 4-10% carbon 
dioxide. The volume was brought up to 500 mL using approximately 470 mL ddH2O 
(double-distilled). Upon completion of this procedure, the color of the MDCK Growth 
Medium was analyzed for a correct pH balance of 7.4. The contents of the bottle were 
then stored at 4C.  
 
MDCK Infection Medium 
Along with MDCK growth medium, MDCK infection medium is also essential. 
The infection medium acts as a viral infection enhancer that allows the facilitation of 
viral penetration, ultimately enhancing productive viral infection of MDCK cells. This 
procedure was performed under a sterile hood using aseptic techniques. The filtration 
system was assembled, in the same way as for the Growth Medium. To the sterile filter-
top, 100 mL 10X MEM, 40 mL 7.5% Bovine Serum Albumin (BSA)-Sigma (15 g BSA 
in 200 mL ddH2O), 10 mL Antibiotic/antimycotic solution, ten mL MEM Vitamin 
Solution, ten mL L-glutamine, and 1 mL Gentamicin (10mg/cc) was added. The volume 
was brought to 500 mL with 329 mL ddH2O. Thirty mL Sodium Bicarbonate was added 
to the filter-top along with 470 mL ddH2O, the pump system was started and upon 
completion of filtration, the medium was mixed and analyzed for correct color, indicating 






Cells were plated using 48-well sterilized plates. The flask containing MDCK 
cells and growth medium was viewed under a microscope to ensure a monolayer was 
produced during cell growth and replication. The growth medium was removed from the 
cell flask and the cells were washed once with sterile PBS. Washing with PBS allows for 
removal of dead cells and excess serum in the growth medium that inhibits trypsin. The 
cells were harvested using 9 mL sterile PBS and 1 mL 0.5% trypsin, adding this solution 
to the flask, and allowing incubation for 1 hour. Trypsin allows for the removal of 
calcium from the cell solution, breaking and separating the cadherins in which the cells 
are held together as well as cutting focal adhesions that anchor the cell to the culture flask 
(Brown et al., 2012).  After incubation, the cells were visualized to ensure the cells were 
suspended in solution. An aliquot of trypsinized cells was collected and centrifuged for 
three minutes at 2500 rpm. The supernatant was removed completely so no residual 
PBS+trypsin covered the cell pellet. The pellet was resuspended in 10 mL of MDCK 
growth medium. In a small test tube, 400 µL of MDCK growth medium was added with 
100 µL of the resuspended cell solution. To ensure confluency of live cells and to reach 
the desired cell count, 500 µL of Trypan Blue was added to the solution. Trypan blue is a 
dye used to quantify live cells by labeling dead cells exclusively. Because live cells have 
an intact cell membrane, trypan blue cannot penetrate the cell membrane of live cells and 
enter the cytoplasm. In a dead cell, trypan blue passes through the porous cell membrane 
and enters the cytoplasm. Ten µL of this solution was added to a hemocytometer and was 
visualized under a microscope. The intact cells were counted and MDCK growth medium 
was added to achieve the desired density of cells per well, 3 x 105. The MDCK cells were 
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then plated on a 48 well plate, with 500 µL in each well. Due to the high growth rate of 
the cells, the cells were split every three days to allow for appropriate space for growth.  
 
TCID50 
One method used to verify the viral titer was the fifty-percent tissue culture 
infective dose (TCID50). This procedure signifies the concentration at which 50% of the 
cells are infected. To begin the TCID50, the collected nasal wash was diluted using 10-
fold serial dilutions. To obtain the desired dilutions, 900 µL of MDCK infection medium 
was added to a series of ten disposable glass test tubes. After adding medium, 100 µL of 
the desired virus sample (nasal wash or lung) was added to the first test tube, to obtain a 
total volume of 1 mL. The samples and all test tube dilutions were kept in an ice bath 
during the procedure to ensure the infectivity was kept intact. The samples were vortexed 
before addition to the plate to ensure proper creation of a homogeneous mixture. From 
the MDCK cells plated a day prior, the medium of the MDCK monolayers was removed 
with a glass pipet. The cells were washed with two separate additions of sterile 1X PBS 
(pH=7.43). After the second wash and removal of PBS, 50 µL of the dilutions were 
added to their respective wells containing the confluent MDCK monolayers. Nasal wash 
dilutions were added starting with medium as a control and then proceeding to add the 
lowest dilution first. Adding the lowest dilution first ensured a higher concentration of 
infected nasal wash was not carried to those with lower concentrations.  Medium was 





Figure 2.1: 48-well plate configuration for serial dilutions of virus stock used for TCID50 protocol. Red 






The cell plates were then incubated at either 37C (for IAV) or 33C (IBV) for 
one hour, allowing for optimal infectivity, with gentle tapping every 15 minutes to ensure 
the sample was evenly distributed across the monolayer of cells. Using 40 mL of MDCK 
infection medium, 40 µL of TPCK-trypsin was added to the test tube. The working 
solution was made for a ratio of 1 µL of 1 mg/mL stock solution per milliliter of MDCK 
infection medium. The cell plates were removed from the incubator and the virus 
inoculum was aspirated off the MDCK monolayer, from most dilute to least, to prevent 
the dragging of higher concentrated virus across the samples. After aspiration, 500 µL of 
contents containing MDCK infection medium supplemented with TPCK-trypsin, was 
added to each individual well. The plates were incubated at 37C (IAV) or 33C (IBV)  
for 72 hours and were observed daily for cytopathic effect (CPE). 
 
Preparation of CRBCs 
 
Influenza viruses have an envelope protein, known as hemagglutinin, that binds to 
sialic acid receptors on cells. The virus will also bind to red blood cells causing the 
formation of a lattice. The binding to red blood cells is the basis of the rapid assay that 
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determines the quantity of virus present. To prepare the red blood cells needed for the HA 
Titer, chicken red blood cells which are shipped in Alsevers solution to prevent 
coagulation of the blood cells, were resuspended and transferred in 12 mL increments 
into two 15 mL conical tubes. The cells were centrifuged using an Eppendorf Centrifuge 
5910 R, for four minutes at 1,338 rpm (357xg) and were kept at 25C. After 
centrifugation, the supernatant was removed, taking special care to preserve the RBC 
layer, but removing the white blood cell (WBC) layer. Ten mL of (1X) PBS was added to 
each tube with the cell layer. The mixture was then centrifuged again for four minutes at 
1,338 rpm (357xg) at 25C. The supernatant was then disposed carefully to preserve the 
cell layer, but removing all PBS added previously. Ten milliliters of (1X) PBS was added 
to each of the tubes. The mixture was centrifuged for 20 minutes at 800 rpm and kept at a 
temperature of 25C. The supernatant was removed once again, to ensure no PBS 
remained in the conical tube. In a sterile bottle, 100 mL of sterile (1X) PBS was added 
and 0.5 mL of RBC from the conical tube was added to the PBS. The RBCs were 
carefully resuspended using a pipette, until the mixture was homogenous. Upon 
completion, the 0.5% CRBCs were stored at 4C. 
 
HA Titer 
 This test relies on the hemagglutination activity of influenza hemagglutinin and 
the ability of HA-specific to agglutinate erythrocytes. Influenza virus particles contain a 
homotrimeric glycoprotein on their surface, hemagglutinin (HA), which causes 
erythrocytes to agglutinate. Hemagglutinin binds to sialic acid receptors on the cells and 
will also bind to erythrocytes causing the formation of a lattice. This property allows for 
the quantification of virus present in a sample.  
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After the 72 hour incubation, the MDCK plates previously inoculated with nasal wash 
were transferred to a 96 well plate. A round-bottom 96-well plate was used to allow the 
red blood cells to settle in the bottom of the well and to decrease the surface area and 
volume of individual wells. From the TCID50 plates, 50 µL from each incubated well was 
transferred to a new well in the 96-well round-bottomed plate. Following the transfer, 50 
µL of 0.5% CRBC solution was added to each well to bring the volume to a total of 100 
µL. The plates were allowed to incubate at room temperature for 30 minutes. The plates 
were then observed and analyzed, with settling of the erythrocytes into a pellet indicating 
the absence of a virus (negative). If settling was not observed and agglutination occurred, 
this indicated that the virus was able to bind to the CRBC solution, indicating that virus 


































 Weight, temperature, and infection of the upper and lower respiratory system 
were monitored daily in the experimentally infected ferrets. According to a study 
conducted by Lee (2010), the most frequent clinical symptoms of influenza infection 
included fever, nausea, and diarrhea. Nausea and diarrhea would lead to a decrease in 
weight, an easy variable to measure in a laboratory setting. Increased body temperature, 
pyrexia, was proven to be the most frequent clinical symptom noted by those infected 
with influenza (Plaza, 2016). Finally, TCID50 and HA titers are ways to both confirm and 
quantify the presence of influenza within the respiratory system. Together, these 
variables were able to characterize the ferret response and virus shedding and localization 
after infection by two types of influenza. The strain of influenza A used within this study 
includes A/California/4/2009-H1N1 (Cal09). The two strains of influenza utilized in this 
study consist of B/Phuket/3073/2013 (BYam lineage, B/Phuket) and B/Brisbane/60/2009 
(BVic lineage, B/Brisbane).  
  
A/California/4/2009-H1N1 
 The weights were recorded for ferrets infected with the Cal09 virus. This influenza 
A virus is similar to what was used in previously published studies and provides a basis for 
the research conducted on influenza B. The animals were monitored for weight loss daily, 
in grams, over a period of nine days. The baseline used for the comparison of data is defined 
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as the data collected on the day of inoculation, representing the norm.  All of the ferrets 
inoculated with the IAV showed a decrease in weight, with peak percent weight losses 
being 9.19% and 8.52%. This data is presented in Figure 3.1 below. A value of (1) on the 
x-axis indicates day zero, in which the ferrets were inoculated. All ferrets included in the 
experiment concerning infection with influenza A exhibited a decrease in weight starting 
the day after inoculation and remained below the baseline for the duration of the study. 
Although the weights remained below the initial weight prior to inoculation for the entirety 
of the experiment, 43.75% of all weights noted, exhibited weight gain when compared to 
the weight recorded on the previous day. When compared to the baseline weight recorded, 
the ferrets exhibited weight changes of -2.72%, -5.50%, -3.91%, and -3.67% on the day 
concluding this experiment.  Rectal temperatures were also recorded over the course of the 
experiment. A normal temperature for a ferret ranges between 37.8 to 39 degrees Celsius 
(Leesville Animal Hospital, 2016). The data collected for temperature comparison 
throughout the experiment can be seen below in Figure 3.2. The animals exhibited body 
temperature changes ranging from 1.39 degrees Celsius to -0.95 degrees Celsius from the 
initial temperature recorded on day 0. Of the sixteen temperatures recorded post-
inoculation, 62.5% of all temperatures recorded, showed an increase from the baseline 
through the duration of the study. Although two ferrets exhibited decreases in body 
temperature for day one post-inoculation, the temperatures eventually rose to above normal 
body temperature recorded prior to infection. All ferrets inoculated with Cal09 showed an 
elevated body temperature at the end of the experiment, day four (depicted by five on the 




Figure 3.1 (left): Percent of weight change in ferrets infected with Cal-09 virus.  
Figure 3.2 (right): Percent of temperature change in ferrets infected with Cal-09 virus.  
 
 
In addition to weight and temperature change, a virus titer was conducted for the 
nasal wash and the lungs. The data showed an initially large presence of influenza virus 
in the nasal wash. The TCID50 values for the ferrets infected with Cal09 can be compared 
and viewed below in Figure 3.3. The nasal wash data from the four ferrets were 
compared based on the TCID50 value of the virus. On day one, the four ferrets showed an 
average TCID50 value of 10
4.5 TCID50/mL. This value denotes the peak concentration of 
Cal09 taking place 24 hours after inoculation. The average TCID50 value then proceeded 
to steadily decrease over the course of four days to a TCID50 value of near 10
1 








Figure 3.3: TCID50 values for ferrets UL-71, LL-72, UR-73, LR-74, over the course of four days.  
 
Along with the nasal wash titer, data were collected to observe the presence of 
Cal09 in the lungs of the four ferrets. Lung titers were conducted upon euthanasia of the 
animals, taking place after nasal wash data was completed. Different sections of the lung 
were collected and combined into a single homogenate. The data in Figure 4.3 shown 
below, illustrates the TCID50 combined lung titer for ferrets inoculated with Cal09. Aside 
from the values obtained, these data show that the virus was able to reach not only the 
nasal wash, but also the lungs. Virus in the nasal turbinates decreased over the course of 
four days post-inoculation, however, virus titers performed on the lung samples after 
nasal wash data collection showed substantial viral activity, indicating the movement of 
influenza A from the upper to the lower respiratory tract. Upon lung data collection on 
day four, the data showed an average TCID50 value of 3.7x10
4 TCID50/mL for the four 
ferrets, indicating viral activity in the lower respiratory system while virus was no longer 
detected in the nasal wash.  
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The ferrets infected with B/Brisbane/60/2008 (BVic) were weighed on the day of 
inoculation, and each day for the following eight days. The weights showed an increase 
from day one to days eight, with the weight remaining above the baseline for all three 
ferrets throughout the duration of the experiment. These data are displayed below in 
Figure 3.5. When the weights were compared on a day to day basis, 83.33% of the total 
recorded weights showed an increase from the previous day. The peak weight loss 
occurred at day seven, with a single ferret exhibiting a weight change of -9.9 grams in 24 
hours, but upon conclusion of this experiment, this particular ferret showed a final 
percent gain of 14.77%, a gain of 133.40 grams. The final weight change from the 
baseline for the three ferrets upon conclusion of the experiment were 14.77%, 17.19%, 
and 14.57%.  The ferrets were monitored daily over a nine-day period for temperature 
changes as well. Animals in the B/Brisbane inoculation group exhibited changes in body 
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temperature that ranged from 1.66 to -0.29 degrees Celsius from the initial temperature 
taken on inoculation day, shown below in Figure 3.6. Of the 24 temperatures recorded 
post-inoculation, 91.97% percent showed an increase in temperature from the initial 
value observed on day 0.  The elevations were first observed on day one post-inoculation 
(day two indicated by Figure 3.6) and were maintained through day nine in all three 
animals. The final temperatures taken on day nine for the three ferrets showed a positive 
value in relation to the baseline.  
 
Figure 3.5 (left): Percent of weight change in ferrets infected with B/Brisbane virus.  
Figure 3.6 (right): Percent of temperature change in ferrets infected with B/Brisbane virus.  
 
The nasal wash TCID50 values were compared for three ferrets over the course of 
seven days, as shown below in Figure 3.7. On day one, the value showed an average of 
103 TCID50/mL for the nasal wash virus titer. The average value then increased until day 
three, to a value of 105 TCID50/mL. After day three, the value drastically decreased over 
the course of two days until a combined average TCID50 value of 10
.5 TCID50/mL was 
obtained. The titer value remained at this value for the next three days indicating no 
further viral activity in the nasal wash. These results indicated that the IBV was present in 
the upper respiratory system until day five post-inoculation. These results resembled the 
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results obtained from the Cal09 inoculum group, indicating similar upper respiratory 
kinetics between the two influenza types. The kinetics between the two types of influenza 
differed in viral infection time and length of infection. Influenza A appeared to peak in 
the nasal wash 24 hours after inoculation, but the virus was no longer active in the upper 
respiratory system at day four. Influenza B, B/Phuket, took three days to reach peak 
upper respiratory infection, and lasted five days post-inoculation.  
 
Figure 3.7: TCID50 values for ferrets UL-61, LL-62, and LR-62, over the course of seven days.  
 
B/Phuket/3073/2013 (BYam) 
B/Phuket/3073/2013 (BYam), was the second influenza B strain utilized for this 
particular study. The B/Phuket virus in the Yamagata lineage, represent one of two 
lineages of influenza virus (BYam and BVic) that have circulated in humans since the 
mid-1980’s and were included in the 2014-15 seasonal influenza vaccination for the 
Northern Hemisphere. Cal09 was used to verify the methods and applied as a control 
group before proceeding with IBV infection. B/Brisbane was used to evaluate the kinetics 
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of upper respiratory infection concerning IBV. Similar methods were used for the 
evaluation of the kinetics of the B/Phuket virus, however a lung titer was included in this 
experiment to observe viral infection of influenza B in the lower respiratory system. The 
four ferrets were monitored for nine days, with weight, temperature, nasal wash titer, and 
lung titer data recorded.  
The weight of four ferrets was recorded for nine days post-inoculation. Like the 
ferrets in the B/Brisbane inoculation group, the weights at day nine were measured as 
above the baseline, as shown below in Figure 3.8. Similarly, a majority of the weights 
remained above the baseline for the duration of the study, fluctuating during the nine day 
experiment. The largest decline in weight could be seen on day two, with two ferrets 
exhibiting an average 1.56% decline in body weight during the 24-hour period. The peak 
weight change below the baseline exhibited a 1.35% decrease but increased to above the 
baseline on the day following. Throughout the experiment, 93.75% of the 32 weights 
recorded, remained at a positive value in relation to the baseline. When compared day to 
day, 68.75% of the total weights recorded, exhibited an increase. These data indicate a 
large fluctuation in weight throughout the experiment. Upon completion of the 
experiment, the final percent weight change for the four ferrets were 6.09%, 8.37%, 
6.01%, and 7.37%. Temperature was monitored and recorded for the B/Phuket inoculum 
group for nine days, shown below in Figure 3.9. The temperature changes ranged from 
1.06 to -0.45 degrees Celsius from the baseline. The increase in temperature can be seen 
on the day following inoculation, similar to the B/Brisbane inoculum group. On day five, 
two ferrets exhibited temperatures below the baseline. The temperatures recorded below 
the baseline were a minor -1.29%, drastically increasing to at or above the baseline on 
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day six. The temperatures then remained elevated after day six for the remainder of the 
experiment. By day nine, all animals held temperatures above the initial baseline. Of the 
32 temperatures recorded through the duration of this experiment, 87.5% exhibited a 
positive value above the baseline.  
 
Figure 3.8 (left): Percent of weight change in ferrets infected with B/Phuket.  
Figure 3.9 (right): Percent of temperature change in ferrets infected with B/Phuket.  
 
Two different B/Phuket inoculum groups were used to examine the kinetics of 
influenza B. The ferrets 51-54 in the first group were used to collect data regarding 
clinical symptoms and nasal wash infectivity. Ferrets 81-84 were used to collect data on 
nasal wash and lung infection. The four ferrets in group one inoculated with B/Phuket 
showed a low nasal wash TCID50 value on day one, an average of 10
1 TCID50/mL. The 
data, shown below in Figure 3.10 shows a drastic increase until day two post-inoculation, 
with a value of 104 TCID50/mL.  These data are similar to what was seen in the 
experiment with B/Brisbane infection. The nasal wash titers then decrease over the 
course of four days to achieve a value equivalent to day one. The value remains at 101 
TCID50/mL for four consecutive days. This indicates no further B/Phuket activity in the 
upper respiratory system, similar to what B/Brisbane and Cal09 exhibited. The length of 
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infection is similar to data observed in the B/Brisbane inoculum group, taking course 
over six days post inoculation.  
 
Figure 3.10: TCID50 values for ferrets UL-51, LL-52, UR-53, and LR-54, over the course of nine days. 
 
 To verify the data collected on B/Phuket, the nasal wash TCID50 values for ferrets 
81-84, were analyzed and recorded in Figure 3.11 below. The day one data appeared to 
be similar to the previous ferrets with a value of 101 TCID50/mL. The data then, similarly, 
increased drastically after day one, except now over the course of two days, 1.25x105. 
This indicated that the virus was able to replicate efficiently and to high titer values. The 
data then decreased at about the same rate as it increased and a value of 7.5x104 
TCID50/mL was observed on day four. This confirms the progression and kinetics of 
B/Phuket in the upper respiratory system. To keep parameters similar to the experiment 
concerning Cal09, lung samples were collected on day five, not allowing the virus to 
reach inactivity in the nasal wash.  
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Figure 3.11: TCID50 values for ferrets UL-81, LL-82, UR-83, and LR-84, over the course of five days. 
 
To evaluate the kinetics of an IBV in the lower respiratory system, lung titers 
were sampled from the second B/Phuket inoculum group. Samples from the B/Phuket 
group, ferrets 81-84, were harvested on day five post-inoculation. The samples were 
homogenized, and the tissue homogenates were clarified by centrifugation and titrated in 
48-well and 96-well tissue culture plates continag a monolayer of MDCK cells. The data 
was obtained in the same way used for nasal wash samples. The data obtained, shown 
below in Figure 3.7, show no presence of virus residing in the lungs at day five in the 
experiment. When compared to Cal09, the lung data provides a difference between 















































In this study, the kinetics of influenza A and B were observed. The variables used 
were able to characterize the ferret response and virus shedding and localization after 
infection with influenza A and B. The influenza A virus used, Cal09, showed viral 
localization in the upper respiratory tract during the beginning of infection. The viral titer 
showed a high presence of virus in the nasal wash shortly after inoculation, with the 
highest virus titer recorded on day one post-inoculation. The viral presence slowly started 
to decrease over the course of infection, until little trace of virus was detected on day 
four. Lung homogenates were collected after viral nasal wash activity was observed, 
showing a positive viral titer for the lower respiratory system. The influenza B viruses, 
B/Brisbane and B/Phuket, showed different viral shedding and localization. In the nasal 
wash, the virus titer did not peak until days two or three post-inoculation. The viral titer 
then decreased over the next few days, with the viral titers indicating viral activity until 
days five to six. These results express the rate of viral infection in the upper respiratory 
system, with influenza A infecting at an increased rate, and only lasting around four days. 
Influenza B, however, took 24-48 hours to reach peak infection, and viral infection lasted 
approximately five to six days. Viral infection was then noted in the lower respiratory 
system, with influenza A showing infection in the lungs, and influenza B (B/Phuket) 
showing no infection in the lungs. These data indicate that influenza A has an increased 
viral infection and localization rate when compared to influenza B.  
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Weight and Temperature 
The weights observed during influenza A infection appear to corelate with the rate 
of infection. On the first few days when maximum virus load was indicated, the weights 
decreased drastically, When virus titers for the nasal wash started to drastically decrease 
around days two and three, the weights began to increase to near the initial weight prior 
to inoculation, but still showed an average percent weight change of -3.95%. The data 
collected indicates that influenza A viral infection does affect weight, but not over a 
substantial amount of time.  In influenza B infection, the weights displayed different 
characteristics, showing almost opposite results. The weights did not appear to correlate 
with the degree of viral infection. Instead, increased weights were observed throughout 
the nine days, regardless of the virus titer for the nasal wash. On day nine, ferrets 
inoculated with B/Brisbane showed an average percent weight change of 15.51%, with 
83.33% of the data showing an increase on a daily basis. This indicates a steady, almost 
linear increase in weight throughout the duration of the experiment. In ferrets inoculated 
with B/Phuket, the weights increased similarly. On day nine, the average percent weight 
gain was 6.96%, with 68.75% of the data displaying an increase in weight on a daily 
basis. When the influenza B infections are grouped together, it can be concluded that 
weight gain is observed during influenza B infection.  
Aside from different characteristics recognized for weight, temperature for 
influenza A and B showed similar characteristics. On day one post-inoculation, half of 
the ferrets infected with influenza A showed a drastic increase in temperature, while the 
other half showed a decrease in temperature. Similar to this finding, the statistics were the 
same when temperature was compared on a day to day basis. Throughout the study, 50% 
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of the data showed an increase in daily temperature while the other 50% showed a 
decrease in daily temperature. Apart from these fluctuations in temperature observed 
during the duration of this study, the temperatures on day four after influenza A infection 
showed an average increase in percent temperature change of 1.81%. The temperature did 
not show a correlation to viral infection on a day to day basis, but upon conclusion of 
experimentation, an increased percent change in temperature of all four ferrets indicates a 
relationship to influenza A infection. The temperature change in influenza B infection 
was more prominent. In B/Brisbane infection, the temperature appeared increase almost 
immediately after inoculation and remained elevated throughout the experiment. On day 
nine, an average percent temperature change of 1.76% was noted. In B/Phuket infection, 
temperature change was similar. The temperature appeared to increase immediately after 
inoculation and remained elevated. On day nine, an average percent temperature change 
of 2.03% was observed. In influenza B infection, it can be concluded that temperature 
will increase during upper respiratory infection, and will remain elevated for days 
following, regardless of detection of virus in the nasal wash. In influenza A infection, it 
can be concluded that temperature may not indicate viral infection on a daily basis, but 
over time a positive percent temperature change can be noticed.  
 
Why Influenza B? 
 
In a study conducted by Lakdawala et al. (2015), on the kinetics of H1N1 pdm 
virus A/California/07/2009, the data published resemble the results and methods 
presented in this study. In the study by Lakdawala, titers were collected and analyzed for 
days one, three, and five in different parts of the respiratory tract. The Cal09 virus 
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showed a positive mean virus titer in the soft palate, nasal wash, right mid lung, and the 
left cranial lung. This indicated that the IAV was able to infect both the upper and lower 
respiratory systems, similar to what was observed in the data concerning Cal09 presented 
in this study. In a different study conducted by Moore et al. (2014), the inoculum volume 
and its effect on clinical disease was evaluated using two strains of IAV. The effects of 
IAV infection were analyzed using recorded data for weight change, temperature change, 
nasal symptoms, and infection in the upper and lower respiratory system. The samples 
quantified using TCID50 values displayed, over a course of six days post-inoculation, that 
the weights of twelve ferrets appeared to decrease at a relatively steady rate (Moore et al., 
2014). This data presented by Moore confirms the results obtained in this study. In 
Moore’s study, the temperature appeared to differ drastically from the baseline over the 
course of six days post-inoculation, in most cases, remaining above the baseline over the 
duration of data collection (Moore et al., 2014). The data presented in this current study, 
resembles the data Moore published as well. The TCID50 values for this current study 
read the highest in the nasal turbinates, but also showed a positive value in the combined 
lung indicating infection in the upper and lower respiratory tract. The same ideas and 
methods from Moore and Lakdawala were applied to this current study, however, for this 
particular study, IBV infection was included. The studies from Lakdawala and Moore 
provide a basis for the study of the kinetics concerning influenza A and lead to the study 







Influenza is a communicable disease that affects both the upper and lower 
respiratory tract. There are four subtypes of influenza, some of these infecting humans 
and others specific to different species (Center for Disease Control and Prevention, 
2019). Influenza virus is transmissible through respiratory droplets expelled from the 
mouth and respiratory system (Boktor, 2019). Influenza can be transmitted before the 
carrier is symptomatic and until five to seven days post-infection (Center for Disease 
Control and Prevention, 2018). It may take a few days to weeks for the carrier to fully 
recover, but complications may arise during this recovery period. The complications that 
may arise are usually inflammation of the upper respiratory tree and the trachea. 
Respiratory complications arising due to influenza infection can develop in as little as 48 
hours from the beginning of symptoms (Boktor, 2019). The virus replicates in the upper 
and lower respiratory passages starting from the time of inoculation and peaking after 48 
hours on average (Boktor, 2019). Research has suggested that influenza A and B are 
different in terms of kinetics within the respiratory tract. This is what is evaluated 
through this study. Influenza viruses replicate in the epithelial cell lining of the upper and 
lower respiratory, and the pathology does not differ between natural or experimental 
infection (Taubenberger, 2008). This allows for the methods used in this study. Many 
studies have been conducted concerning the kinetics of influenza A. This study has 
verified that influenza A, specifically strain Cal09, infects the upper respiratory system 
and well as the lower. The study by Moore et al. (2014), concluded that within 
experimental infection, influenza A was able to infect the nasal wash and two locations in 
the lung. The researchers showed that the virus was able to infect a larger portion of the 
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lung sections as the inoculum volume was increased (Moore et al., 2014). They were able 
to conclude that the inflammatory response was most intense on day six following 
inoculation. In this study, it was verified that influenza A infection in the nasal wash 
peaks around 0-48 hours post infection. The titer value then showed a steady decrease as 
the host cleared the virus from the upper respiratory tract. Upon completion of nasal wash 
collection, the ferrets were euthanized, and the lungs were sampled. The titer verified that 
there was influenza A virus present in the lungs at this time, with little to no virus present 
in the nasal wash.  
Similar procedures were used for the evaluation of influenza B. Less information 
is known about the kinetics of influenza B, making it hard to fully determine if IBV 
infects the lower respiratory system. The first virus used, B/Brisbane, confirmed infection 
of the upper respiratory system. However, unlike influenza A, the virus titer showed a 
peak concentration on day three, 72 hours after inoculation. The titer value then 
drastically decreased until little to no virus was present. Another virus, B/Phuket, was 
used to study infection of the lower respiratory system. B/Phuket showed nasal wash 
virus titers similar to Cal09 and B/Brisbane. The virus titer showed the highest on day 
two, but still remained quite high on day three. The titer for B/Phuket then dropped to a 
value indicating no viral activity around day six. Regardless of the small inconsistencies, 
in all three strains of influenza, the virus titer peaked around 48 hours post infection, and 
was no longer active in the upper respiratory tract around day five. The lung titer was 
then analyzed to determine the presence of B/Phuket in the lower respiratory system. 
There was no presence of virus in any of the four ferrets inoculated with B/Phuket. The 
information presented in this report confirms the kinetics of influenza A and B in the 
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upper respiratory system and also confirms that although influenza A infects the lower 
respiratory system, influenza B (B/Phuket) does not. B/Brisbane was not included in lung 
sampling, therefore, further research would need to be conducted to confirm the lung 
infectivity of this type of influenza B virus.  
Conclusion 
In this study, the kinetics of influenza A was verified and determined to infect 
both the upper and lower respiratory systems. The experiments evaluating influenza B 
were able to verify that the IBV infects the upper respiratory system, but no sign of lower 
respiratory infection was found in this study. Currently, little is known about the viral 
kinetics of influenza A and B during infection within an individual. World-wide 
influenza outbreaks can be very costly in terms of human life, infecting nearly 20-50 
million people in the United States alone and causing an estimated 30-40,000 deaths per 
year. Influenza viruses have an extremely high mutation rate, providing a large hurdle for 
effective vaccinations. This constant change creates an unquestionable need for intensive 
basic and clinical influenza research. The goal is to recognize and anticipate how the 
viruses are evolving. This includes the kinetics and the replication of the virus. This 
thorough understanding is the first step toward creating accurate and useful antiviral 
therapies for influenza. As seen in the world today with COVID-19, not understanding 
the kinetics and infectivity of a virus can be particularly damaging to the population and 
economy. Influenza has been around for hundreds of years, allowing adequate time for 
extensive research. Research such as this is needed to keep up with the quickly evolving 
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